These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28010996)

  • 21. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
    Romero TR; Pacheco Dda F; Duarte ID
    Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice.
    Zhang R; Lao K; Lu B; Guo H; Cheng J; Chen P; Gou X
    Peptides; 2021 Feb; 136():170442. PubMed ID: 33171279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice.
    Han ZL; Wang ZL; Li XH; Li N; Pan JX; Zheng T; Fang Q; Wang R
    Anesth Analg; 2015 Nov; 121(5):1360-8. PubMed ID: 26273748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anorexigenic effects induced by RVD-hemopressin(α) administration.
    Ferrante C; Recinella L; Leone S; Chiavaroli A; Di Nisio C; Martinotti S; Mollica A; Macedonio G; Stefanucci A; Dvorácskó S; Tömböly C; De Petrocellis L; Vacca M; Brunetti L; Orlando G
    Pharmacol Rep; 2017 Dec; 69(6):1402-1407. PubMed ID: 29145068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
    Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
    Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.
    Macedonio G; Stefanucci A; Maccallini C; Mirzaie S; Novellino E; Mollica A
    Protein Pept Lett; 2016; 23(12):1045-1051. PubMed ID: 27748182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of receptor binding and functional characteristics of hemopressin(1-7).
    Dvorácskó S; Tömböly C; Berkecz R; Keresztes A
    Neuropeptides; 2016 Aug; 58():15-22. PubMed ID: 26895730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.
    Keenan CM; Storr MA; Thakur GA; Wood JT; Wager-Miller J; Straiker A; Eno MR; Nikas SP; Bashashati M; Hu H; Mackie K; Makriyannis A; Sharkey KA
    Br J Pharmacol; 2015 May; 172(9):2406-18. PubMed ID: 25572435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central functional response to the novel peptide cannabinoid, hemopressin.
    Dodd GT; Worth AA; Hodkinson DJ; Srivastava RK; Lutz B; Williams SR; Luckman SM
    Neuropharmacology; 2013 Aug; 71():27-36. PubMed ID: 23542442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CB2 cannabinoid receptor mediation of antinociception.
    Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
    Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative allosteric modulation of CB
    Iyer V; Saberi SA; Pacheco R; Sizemore EF; Stockman S; Kulkarni A; Cantwell L; Thakur GA; Hohmann AG
    Neuropharmacology; 2024 Oct; 257():110052. PubMed ID: 38936657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
    Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
    ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system.
    Khakpai F; Ebrahimi-Ghiri M; Alijanpour S; Zarrindast MR
    Biomed Pharmacother; 2019 Apr; 112():108717. PubMed ID: 30970516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
    Salussolia CL; Nalwalk JW; Hough LB
    Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The electrophysiological and behavioral evaluation of the peptide hemopressin and cannabinoid CB1 receptor agonist and antagonist in pentylenetetrazol model of epilepsy in rats.
    Al-Kaleel A; Aygun H; Al-Gailani L; Kabak Y; Inal S; Ayyildiz M; Him A; Agar E
    Pflugers Arch; 2023 Jun; 475(6):719-730. PubMed ID: 37100982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cannabinoid receptors in hepatic fibrosis and apoptosis associated with bile duct ligation in rats.
    Mahmoud MF; Swefy SE; Hasan RA; Ibrahim A
    Eur J Pharmacol; 2014 Nov; 742():118-24. PubMed ID: 25179573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.